Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Reports Stock Transactions
SEC Form 4
CEO Samarth Kulkarni reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations, along with adjustments to holdings in a trust.
Summary
- On March 20, 2025, Samarth Kulkarni, CEO of CRISPR Therapeutics, reported the vesting of 19,688 common shares from restricted stock units.
- Kulkarni also sold 10,031 shares on March 21, 2025, at a price of $41.23 per share to cover tax withholding obligations related to the vesting of the restricted stock units.
- Following these transactions, Kulkarni directly owns 195,085 common shares and indirectly owns 85,622 shares through The Kulkarni 2023 GRAT.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions, with no inherent positive or negative sentiment.
Future Outlook
The restricted stock units will continue to vest in quarterly installments on March 20 of 2026, 2027, and 2028.
Management Comments
- The sale of shares was mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, often related to compensation packages and tax obligations.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term company performance.
- Sales of shares to cover tax obligations upon vesting are a standard practice among executives in publicly traded companies.
- Comparable companies such as Editas Medicine and Intellia Therapeutics also have executives who regularly report stock transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares, but the impact is likely minimal given the relatively small volume.
Key Dates
| Date | Description |
|---|---|
| 03/20/2024 | Date of grant for restricted stock unit award with respect to 78,750 Common Shares. |
| 03/20/2025 | Date of vesting of 19,688 common shares from restricted stock units. |
| 03/20/2025 | One quarter of the shares vesting. |
| 03/21/2025 | Date of sale of 10,031 shares at $41.23 per share. |
| 03/20/2026 | One quarter of the shares vesting. |
| 03/20/2027 | One quarter of the shares vesting. |
| 03/20/2028 | One quarter of the shares vesting. |
| 03/24/2025 | Date of signature by attorney-in-fact. |
Keywords
CRISPR Therapeutics, Samarth Kulkarni, stock transactions, Form 4, restricted stock units, common shares, CEO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.